ǰÑÔ
ϵͳÐÔºì°ßÀÇ´¯(systemic lupus erythematosus,SLE)ÊÇÒ»ÖÖ×ÔÉíÃâÒ߽鵼µÄ£¬ÒÔÃâÒßÐÔÑ×֢Ϊͻ³öÌåÏֵģ¬ÀÛ¼°¶àϵͳ¡¢¶àÆ÷¹Ù¡¢¶à×éÖ¯Ë𺦵ÄÂýÐÔÈ«ÉíÐÔ¼²²¡¡£ÑªÇåÖб£´æÒÔ¿¹ºË¿¹Ìå¡¢¿¹dsDNA¿¹ÌåΪ´ú±íµÄ¶àÖÖ×ÔÉí¿¹Ìå¡£ÁÙ´²ÌåÏÖΪºã¾ÃµÍ¡¢Öжȷ¢ÈÈ£¬·¦Á¦¡¢ÌåÖØ¼õÇá£¬Ãæ¼Õ²¿µûÐκì°ß£¬ÊàŦÌÛÍ´£¬ÐİüÑ×£¬¼äÖÊÐÔ·ÎÑ×£¬ÀÇ´¯ÐÔÉöÑס¢Éñ¾ÏµÍ³¸Ä±äµÈÈ«ÉíÐÔÖ¢×´¡£»¯Ñé¼ì²éѪºìÂѰ×Ͻµ£¬°×ϸ°û»òѪС°åïÔÌ£¬»¼ÕßѪÇå¿É²éµ½¶àÖÖ¿¹ºË¿¹Ìå¡¢¿¹Á×Ö¬¿¹ÌåºÍ¿¹×é֯ϸ°û¿¹Ì塣ѪÇå×ܲ¹Ì庬ÃÍϽµ£¬ÓÈÆäÊÇC3º¬Á¿µÍÏÂÌåÏÖΪÔ˶¯ÆÚ¡£
SLEÊÇÒ»ÖÖ³£¼ûµÄÄÑÖÎÐÔ¼²²¡£¬ËäÈ»ÏÖÒÑÃ÷È·SLEÊÇÒ»ÖÖ×ÔÉíÃâÒß²¡£¬µ«È·Çв¡ÒòºÍ·¢²¡»úÖÆÉÐδÍêÈ«ÆÊÎö¡£Ò»Ñùƽ³£ÒÔΪÖ÷ÒªÓëÒÅ´«Óйأ¬ÇéÐÎÒòËØÊÇÒ»¸ö´ÎÒªÒòËØ¡£ÓÉÓÚSLE»¼ÕßÅ®ÐÔÏÔ×ŶàÓÚÄÐÐÔ(9:1),XȾɫÌå±àÂëµÄ»ùÒò¿ÉÄÜÓë´Ë²¡Óйء£ÕýÓÉÓÚÔÆÔÆ£¬ÔËÓÃÖÖÖÖ¶¯ÎïÄ£×Ó´Ó²î±ð½Ç¶È¶Ô̽ÌÖ±¾²¡µÄ·¢²¡»úÖÆ¡¢²¡Àíת±äºÍÖÎÁÆÒªÁì¾ßÓÐÖ÷ÒªÒâÒå¡£
SLE¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ¶¯ÎïÄ£×Ó¡¢×Ô¾õÐÔ¶¯ÎïÄ£×ӺͻùÒòÐÞÊζ¯ÎïÄ£×Ó3Àà¡£
ÓÃÓÚÑо¿×ÔÉíÃâÒßÐÔ¼²²¡µÄ»ùÒòÐÞÊÎСÊóÄ£×ÓÖÖÀàÐí¶à£¬Èçת»ùÒòСÊóÄ£×ÓB6.CgTg(Actb-TNFRSF6B)754Jwu/J¡¢»ùÒòÇÃÈëСÊóÄ£×Ó129S6.129X1(B6)-PtprctmlWeis/JºÍB6.129X1PtprctmlWeis/J¡¢»ùÒòÇóýСÊóÄ£×ÓB6.129S6(Cg)-CdknlatmlLed/J¡¢B6;129S-Fcgr2btmlTtK/J£¬Ìõ¼þÐÔ»ùÒò´ò°ÐСÊóÄ£×ÓB6.Cg£RxratmlKrc/JµÈ20Óà¸öƷϵ¡£ÓÉÓÚSLEÊǶà»ùÒòÒÅ´«£¬¶øÏÖÔÚ»ùÒòÐÞÊÎÊÖÒÕ½öÊÇÔöÌí»òÇóý1¸ö»ùÒò£¬Æä±íÐÍÖ»ÊDz¿·ÖÄ£ÄâºÍÀàËÆÓÚÈËSLEµÄÁÙ´²ÌåÏֺͲ¡Àí¸Ä±ä£»ÁíÍ⣬һ¸ö»ùÒò²úÆ·ÔÚÌåÄÚ²î±ðÆ÷¹ÙµÄ±í´ï»á±¬·¢²î±ðµÄÉúÎïѧЧӦ£¬ÔöÌí»òÇóý1¸ö»ùÒò³ýÁ˱¬·¢ÎÒÃÇÔ¤ÆÚµÄÌØ¶¨¼²²¡µÄÌåÏÖÍ⣬»¹¿ÉÄܱ¬·¢ÆäËü·½ÃæµÄ²¡Àí¸Ä±ä£¬Õâ´ÓÒÅ´«½Ç¶ÈÆÊÎöÏ¢ÕùÊÍSLEµÄ·¢²¡»úÀíÉÏÓÐÒ»¶¨µÄ¾ÖÏÞÐÔ¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
¸ÃƷϵСÊóÔÚÈËβ¼¡¶¯ÂÑ°×Æô¶¯×ӵĿØÖÆÏ±í´ïÈËÖ×Áö»µËÀÒò×ÓÊÜÌ峬µÈ¼Ò×å6B (TNFRSF6B)»ùÒò¡£´ÆÐÔСÊó·ºÆðÏÔ×ŵÄÀÇ´¯ÑùÖ¢×´£¬ÆäÌØÕ÷ÊÇÁÜͶºÏ²¡¡¢Æ¢´ó¡¢¿¹ºËºÍ¿¹dsDNA¿¹Ìå¡¢ÉöСÇòÉöÑס£
¡¾ÔìÄ£ÒªÁì¡¿£º
ÍâÔ´»ùÒò¹¹¼þ°üÀ¨ÈËβ¼¡¶¯µ°°ÙÆô¶¯×Ó¡¢ÈËTNFRSF6BcDNAºÍÈËβ¼¡¶¯ÂѰ׵ÄpolyAÐźš£ÓÃÏÔ΢עÉä·¨½«ÍâÔ´»ùÒò¹¹¼þ×¢Èëµ½(C3HXC57BL/6) F1СÊóµÄÐÛÐÔÔºËÖС£Ëæºó½«×ª»ùÒòСÊóÓëÒ°ÉúÐÍC57BL/6СÊ󻨽»£¬½«ÍâÔ´»ùÒòµ¼Èëµ½C57BL/6СÊóÅä¾°ÖС£
¡¾Ä£×ÓÌØµã¡¿£º
¸Ãת»ùÒòСÊ󱬷¢ÓëÈËSLEÏàËÆµÄ×ÔÉíÃâÒßÐÔ¼²²¡¡£ÔÚ4~6¸öÔ±¬·¢¾ßÓÐÒ쳣ϸ°û±íÐ͵ÄÁܰÍÏÙ²¡£¬Æ¢´ó¡£¸Ã±íÐÍÖ÷Òª±¬·¢ÔÚ´ÆÐÔ(64.5%£©£¬¶øÐÛÐÔÖ»ÓÐ20%¡£ÆäËûÖ¢×´°üÀ¨¿¹ºË¿¹ÌåºÍ¿¹dsDNA¿¹Ìå¡¢¸¹Ç»B-1aÑÇȺÔöÌí¡¢ÉöСÇòÉöÑ×ÓÐIgGºÍC3³Á»ý¡¢ÂѰ×Äò¡¢ÑªÄòºÍ°×ϸ°ûÄò¡£Ëæ×ÅÔÂÁäÔö´ó£¬·ºÆðƤË𣬸ÎÔàÁܰÍϸ°û½þÈó£¬ÑªÐ飬°×ϸ°ûºÍѪС°åïÔÌ¡£63£¥´ÆÐÔºÍ81.8£¥ÐÛÐÔ´æ»îÁè¼Ý14¸öÔ¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
´ËÄ£×Ó¿ÉÓÃÓÚSLE²¡Òò¡¢·¢²¡»úÖÆ¡¢×ÔÉíÃâÒßÐÔ¼²²¡µÄÃâÒßµ÷ÀíÒÔ¼°ÖÎÁÆSLEÒ©ÎïµÄҩЧѧÑо¿µÈ¡£ÊµÑéʱÓÃC57BL/6×÷ΪÒõÐÔ±ÈÕÕ¡£
²Î¿¼ÎÄÏ×£º
1.¬ÁÕ£¬ÞÉ»ª¹ú£¬ÎâºñÉú£®»î»¯ÁܰÍϸ°û¼°ÆäȾɫÖÊÓÕµ¼¿¹ºË¿¹ÌåÌìÉú£®ÖлªÎ¢ÉúÎïѧºÍÃâÒßѧÔÓÖ¾£¬1999, 19(1):44-46
2.Àî½ðÖ¦£¬¶¡öÁ£¬Merim Boukherouba£¬µÈ£®PristaneÓÕµ¼Ð¡ÊóϵͳÐÔºì°àÀÇ´¯¶¯ÎïÄ£×ÓµÄÑо¿£®Ï¸°ûÓë·Ö×ÓÃâÒßѧÔÓÖ¾£¬2011,27(2): 119-122
3.ÂÞÑåÑ壬ÁÖÓÐÀ¤£¬»Æ´äÀö£¬µÈ£®¸Îϸ°ûÖÊÂѰ×ÓÕµ¼ÏµÍ³ÐÔºì°ßÀÇ´¯ÍÃÄ£×ÓµÄʵÑéÑо¿. ÃâÒßѧÔÓÖ¾£¬2011,27 (8):710-714
4.Bubier JA,Sproule TJ,Foreman O,el al. A critical role for TL-21 receptor signaling in the pathogenesis of systemic lupus erythemalosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A,2009, 106(5): 1518-1523
5.Chen J, Kubalak SW, Chien KR. Ventricular musclerestricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development, 1998, 125 (10): 1943-1949
6.Dubois EL,Horowitz RE,Demopoulos HB,et al. NZB/ NZW mice as a model of systemic lupus erythematosus£®JAMA, 1966, 195 (4):285-289
7.Han B,Moore PA, Wu J,et al. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosuslike synclrome. Arthritis Rheum, 2007,56 (11):3748-3758
8.Satoh M. Richards HB, Shaheen VM, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoanlibodies by pristane. Clin Exp lmmunol, 2000, 121(2):399-405
9.Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristine. J Exp Med, 1994, 180 (6):2341-2346
10.Takai T, Ono M, Hikida M, et al. Augmented humoral and anaphylaclic responses in Fc gamma R¢ò-deficienl mice. Nature, 1996,379(6563):346-349